Literature DB >> 2502336

Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice.

H F Lecoeur1, P H Lagrange, C Truffot-Pernot, M Gheorghiu, J Grosset.   

Abstract

Three strains of mice (Swiss albinos, C57BL/6,C3H/OuJ) were injected intravenously with 3.7 x 10(6) colony forming units (CFU) of M. tuberculosis, H37RV, sensitive and resistant to antibiotics (90% of bacilli sensitive, 9% resistant to Streptomycin and 0.9% resistant to Kanamycin). Two weeks later, chemotherapy was started 6 days a week for a 6-month period with isoniazid (INH) and rifampicin (RMP). Twenty mice of each strain were killed at the end of the chemotherapy and the others were kept without antibiotics for a second 6-month follow-up period before being killed. The early multiplication of bacilli during the first 2 weeks following infection and before chemotherapy, was similar in the three strains of mice. Chemotherapy had the same apparent efficacy in the three strains of mice, nearly all the mice being cured as assessed by a negative spleen culture on Loewenstein-Jensen medium at the end of chemotherapy. But after the 6-month follow-up period, the C3H strain presented a statistically significantly higher level of positive spleen culture ('relapse') than seen in the C57BL/6 strain, and an increased number of mycobacteria per relapsing mouse spleen. It has been estimated with the help of resistant and sensitive bacilli that the relapses were due in most of the cases to the regrowth of one or very few bacilli, giving a clone. It seems that the C3H strain of mice, known to carry the Bcg-r allele of the Bcg gene, might be less able to develop a specific acquired resistance capable of stopping the delayed development of a highly virulent strain of mycobacteria.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502336      PMCID: PMC1541904     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  The role of host factors for the chemotherapy of BCG infection in inbred strains of mice.

Authors:  J H Cox; J Ivanyi
Journal:  APMIS       Date:  1988-10       Impact factor: 3.205

2.  Genetics of resistance to infection with Salmonella typhimurium in mice.

Authors:  J Plant; A A Glynn
Journal:  J Infect Dis       Date:  1976-01       Impact factor: 5.226

3.  Are the Lsh and Ity disease resistance genes at one locus on mouse chromosome 1?

Authors:  J E Plant; J M Blackwell; A D O'Brien; D J Bradley; A A Glynn
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

4.  Expression of the natural resistance gene Lsh in resident liver macrophages.

Authors:  P R Crocker; J M Blackwell; D J Bradley
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

5.  Phenotypic expression of genetically-controlled natural resistance to Mycobacterium bovis (BCG).

Authors:  J L Stach; P Gros; A Forget; E Skamene
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

6.  Regulation of resistance to leprosy by chromosome 1 locus in the mouse.

Authors:  E Skamene; P Gros; A Forget; P J Patel; M N Nesbitt
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

7.  Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice.

Authors:  P Gros; E Skamene; A Forget
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

8.  Inbred mouse strain resistance to Mycobacterium lepraemurium follows the Ity/Lsh pattern.

Authors:  I N Brown; A A Glynn; J Plant
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

9.  Immunopathology of BCG infection in genetically resistant and susceptible mouse strains.

Authors:  M Pelletier; A Forget; D Bourassa; P Gros; E Skamene
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

10.  H-2-linked gene(s) influence the granulomatous reaction to viable Mycobacterium lepraemurium in the mouse.

Authors:  O Closs; M Løvik; H Wigzell; B A Taylor
Journal:  Scand J Immunol       Date:  1983-07       Impact factor: 3.487

View more
  9 in total

1.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis.

Authors:  A A Chackerian; T V Perera; S M Behar
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

4.  Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models.

Authors:  Paul J Converse; Petros C Karakousis; Lee G Klinkenberg; Anup K Kesavan; Lan H Ly; Shannon Sedberry Allen; Jacques H Grosset; Sanjay K Jain; Gyanu Lamichhane; Yukari C Manabe; David N McMurray; Eric L Nuermberger; William R Bishai
Journal:  Infect Immun       Date:  2008-12-22       Impact factor: 3.441

5.  Man and mouse TB: contradictions and solutions.

Authors:  Alexander Apt; Igor Kramnik
Journal:  Tuberculosis (Edinb)       Date:  2009-04-02       Impact factor: 3.131

6.  Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.

Authors:  Nicholas D Walter; Sarah E M Born; Gregory T Robertson; Matthew Reichlen; Christian Dide-Agossou; Victoria A Ektnitphong; Karen Rossmassler; Michelle E Ramey; Allison A Bauman; Victor Ozols; Shelby C Bearrows; Gary Schoolnik; Gregory Dolganov; Benjamin Garcia; Emmanuel Musisi; William Worodria; Laurence Huang; J Lucian Davis; Nhung V Nguyen; Hung V Nguyen; Anh T V Nguyen; Ha Phan; Carol Wilusz; Brendan K Podell; N' Dira Sanoussi; Bouke C de Jong; Corinne S Merle; Dissou Affolabi; Helen McIlleron; Maria Garcia-Cremades; Ekaterina Maidji; Franceen Eshun-Wilson; Brandon Aguilar-Rodriguez; Dhuvarakesh Karthikeyan; Khisimuzi Mdluli; Cathy Bansbach; Anne J Lenaerts; Radojka M Savic; Payam Nahid; Joshua J Vásquez; Martin I Voskuil
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

7.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

8.  Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.

Authors:  Devyani Deshpande; Shashikant Srivastava; Eric Nuermberger; Jotam G Pasipanodya; Soumya Swaminathan; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

Review 9.  One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.

Authors:  Hee-Jeong Yang; Decheng Wang; Xin Wen; Danielle M Weiner; Laura E Via
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.